MorphoSys AG — Regulatory Filings 2002

Jul 1, 2002

News Details

Ad-hoc | 1 July 2002 07:23

MorphoSys AG english

MorphoSys and Roche Announce Major Milestone in Research Collaboration Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys AG (Neuer Markt: MOR), the Munich-based Biotechnology Company, and Roche today announced the achievement of an important milestone in their collaboration. In achieving the milestone MorphoSys generated and delivered several antibodies meeting predefined Roche success criteria. Roche will now further characterize the antibodies in preclinical studies and thereafter determine the most promising antibody in clinical trials. This achievement triggered an undisclosed milestone payment from Roche to MorphoSys. MorphoSys and Roche initiated the collaboration to develop human antibodies targeting a Roche Alzheimer’s disease target in September 2000. MorphoSys used its proprietary HuCAL library to generate several antibodies against the Roche target, hitting the first two milestones in December 2000 and March 2001. In achieving these two milestones MorphoSys delivered a series of HuCAL antibodies which were shown to bind selectively to the Roche target in human Alzheimer brain tissue sections. For the most recent milestone MorphoSys generated HuCAL antibodies demonstrating high affinity binding to the Roche target in both in vitro assays and in an Alzheimer’s animal model. MorphoSys will receive development related milestone payments and royalties on any marketed products emerging from the collaboration. end of ad-hoc-announcement (c)DGAP 01.07.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 010723 Jul 02